Falcon Point Capital’s Harvard Bioscience HBIO Stock Holding History

Falcon Point Capital’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,283	Closed	-$206K	–	112
2019 Q2	$206K	Sell	10,283 -152	-1%	-$4.45K	0.11%	94
2019 Q1	$450K	Buy	+10,435	New	+$378K	0.25%	69

Other funds holding HBIO

ECM

Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

DGHMC

Dalton, Greiner, Hartman, Maher & Co New York $126M AUM 92.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Falcon Point Capital's HBIO Position: Q3 2019 in Review

Falcon Point Capital sold out of Harvard Bioscience (HBIO) in Q3 2019, closing a stake of 10,283 shares — an estimated $206K sold.

Falcon Point Capital first reported a position in HBIO in Q1 2019 and held it in 2 quarters. The position peaked at $450K in Q1 2019. 71 funds tracked by Wall St. Rank hold HBIO as of Q3 2019.

Falcon Point Capital reported no remaining Harvard Bioscience position as of Q3 2019 after selling out during the quarter.
Falcon Point Capital sold 10,283 Harvard Bioscience shares in Q3 2019, an estimated $206K.
Falcon Point Capital first reported a position in Harvard Bioscience in Q1 2019 and held it in 2 quarters.
Falcon Point Capital's Harvard Bioscience position peaked at $450K in Q1 2019.
71 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2019.

Based on Falcon Point Capital's 13F filing for Q3 2019, filed 13 Nov 2019.